HRP990188A2 - Diaza-spiro /3,5/ nonane derivatives - Google Patents

Diaza-spiro /3,5/ nonane derivatives Download PDF

Info

Publication number: HRP990188A2
Authority: HR; Croatia
Prior art keywords: phenyl; spiro; diaza; nonan; naphthalen
Prior art date: 1998-06-12

Application number

HR98110804.6A

Other languages

English (en)

Croatian (hr)

Inventor

Adam Geo

Andrea Cesura

Francois Jenck

Sabine Kolczewski

Stephan Roever

Juergen Wichmann

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-12

Filing date

1999-06-11

Publication date

2000-02-29

1999-06-11 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2000-02-29 Publication of HRP990188A2 publication Critical patent/HRP990188A2/hr

Links

BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical class CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims description 102
239000000203 mixture Substances 0.000 claims description 35
-1 bicyclo[3.3.1]non-9-yl Chemical group 0.000 claims description 24
108090000622 Nociceptin Proteins 0.000 claims description 18
238000000034 method Methods 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 17
125000000217 alkyl group Chemical group 0.000 claims description 16
PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 claims description 15
238000006243 chemical reaction Methods 0.000 claims description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
208000002193 Pain Diseases 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
TYBCSQFBSWACAA-UHFFFAOYSA-N Nonan-4-one Chemical compound CCCCCC(=O)CCC TYBCSQFBSWACAA-UHFFFAOYSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
230000001154 acute effect Effects 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
208000024827 Alzheimer disease Diseases 0.000 claims description 4
208000000044 Amnesia Diseases 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 4
208000027796 Blood pressure disease Diseases 0.000 claims description 4
208000000094 Chronic Pain Diseases 0.000 claims description 4
206010010904 Convulsion Diseases 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 4
208000026139 Memory disease Diseases 0.000 claims description 4
208000008589 Obesity Diseases 0.000 claims description 4
208000013200 Stress disease Diseases 0.000 claims description 4
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 4
208000005298 acute pain Diseases 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
230000004872 arterial blood pressure Effects 0.000 claims description 4
230000036461 convulsion Effects 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
206010015037 epilepsy Diseases 0.000 claims description 4
230000029142 excretion Effects 0.000 claims description 4
208000014674 injury Diseases 0.000 claims description 4
230000006984 memory degeneration Effects 0.000 claims description 4
208000023060 memory loss Diseases 0.000 claims description 4
208000030159 metabolic disease Diseases 0.000 claims description 4
230000000926 neurological effect Effects 0.000 claims description 4
235000020824 obesity Nutrition 0.000 claims description 4
230000008733 trauma Effects 0.000 claims description 4
GSUUINFTNAGZDH-UHFFFAOYSA-N 7-cyclooctyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCCC1 GSUUINFTNAGZDH-UHFFFAOYSA-N 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
238000006268 reductive amination reaction Methods 0.000 claims description 3
AJYMZRDFCFFPPR-UHFFFAOYSA-N 7-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-yl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound O=C1CC2(CCN(CC2)C2CC3CCCCC3CC2)N1C1=CC=CC=C1 AJYMZRDFCFFPPR-UHFFFAOYSA-N 0.000 claims description 2
YNQHGZPSSJWKSX-UHFFFAOYSA-N 7-cycloheptyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCC1 YNQHGZPSSJWKSX-UHFFFAOYSA-N 0.000 claims description 2
XFUQQZWGUPWDLW-UHFFFAOYSA-N 7-cyclononyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCCCC1 XFUQQZWGUPWDLW-UHFFFAOYSA-N 0.000 claims description 2
VITXVCYZJIGRMI-UHFFFAOYSA-N 7-cyclononyl-1-phenyl-1,7-diazaspiro[3.5]nonane Chemical compound C=1C=CC=CC=1N1CCC1(CC1)CCN1C1CCCCCCCC1 VITXVCYZJIGRMI-UHFFFAOYSA-N 0.000 claims description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
YOMSZEJVVGTTDO-KDURUIRLSA-N CC(C)[C@H]1CC[C@H](CC1)N1CCC2(CC(=O)N2c2ccccc2)CC1 Chemical compound CC(C)[C@H]1CC[C@H](CC1)N1CCC2(CC(=O)N2c2ccccc2)CC1 YOMSZEJVVGTTDO-KDURUIRLSA-N 0.000 claims description 2
MEBVZOCGRFHLIS-BGYRXZFFSA-N CC(C)[C@H]1CC[C@H](CC1)N1CCC2(CCN2c2ccccc2)CC1 Chemical compound CC(C)[C@H]1CC[C@H](CC1)N1CCC2(CCN2c2ccccc2)CC1 MEBVZOCGRFHLIS-BGYRXZFFSA-N 0.000 claims description 2
125000004094 acenaphthen-1-yl group Chemical group [H]C1=C([H])C2=C3C(=C([H])C([H])=C([H])C3=C1[H])C([H])([H])C2([H])* 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 claims description 2
125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 claims description 2
102000048266 Nociceptin Human genes 0.000 claims 4
201000010099 disease Diseases 0.000 claims 3
206010013663 drug dependence Diseases 0.000 claims 1
208000011117 substance-related disease Diseases 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 59
238000007429 general method Methods 0.000 description 51
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 43
239000007787 solid Substances 0.000 description 38
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 27
VKCYHJWLYTUGCC-UHFFFAOYSA-N nonan-2-one Chemical compound CCCCCCCC(C)=O VKCYHJWLYTUGCC-UHFFFAOYSA-N 0.000 description 26
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
238000002844 melting Methods 0.000 description 21
230000008018 melting Effects 0.000 description 21
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
239000001530 fumaric acid Substances 0.000 description 16
102400001111 Nociceptin Human genes 0.000 description 14
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
PBIUDEUWYGBHDW-UHFFFAOYSA-N 2-chloro-1-pyridin-3-ylethanone;hydrochloride Chemical compound Cl.ClCC(=O)C1=CC=CN=C1 PBIUDEUWYGBHDW-UHFFFAOYSA-N 0.000 description 11
PVXPBVFOSCAEHS-UHFFFAOYSA-N 1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C=1C=CC=CC=1N1C(=O)CC21CCNCC2 PVXPBVFOSCAEHS-UHFFFAOYSA-N 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
239000000243 solution Substances 0.000 description 9
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
239000000047 product Substances 0.000 description 8
238000006722 reduction reaction Methods 0.000 description 8
239000000829 suppository Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 7
150000003840 hydrochlorides Chemical class 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
108010020615 nociceptin receptor Proteins 0.000 description 6
FPKISACHVIIMRA-UHFFFAOYSA-N 4-propan-2-ylcyclohexan-1-one Chemical compound CC(C)C1CCC(=O)CC1 FPKISACHVIIMRA-UHFFFAOYSA-N 0.000 description 5
238000009833 condensation Methods 0.000 description 5
230000005494 condensation Effects 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
BIMZZJDNYSFXCL-UHFFFAOYSA-N 4-methyl-1,3-dihydroinden-2-one Chemical compound CC1=CC=CC2=C1CC(=O)C2 BIMZZJDNYSFXCL-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
SXVPOSFURRDKBO-UHFFFAOYSA-N Cyclododecanone Chemical compound O=C1CCCCCCCCCCC1 SXVPOSFURRDKBO-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
241000700159 Rattus Species 0.000 description 4
239000013543 active substance Substances 0.000 description 4
239000000556 agonist Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
238000005984 hydrogenation reaction Methods 0.000 description 4
UMJJFEIKYGFCAT-UHFFFAOYSA-N indan-2-one Chemical compound C1=CC=C2CC(=O)CC2=C1 UMJJFEIKYGFCAT-UHFFFAOYSA-N 0.000 description 4
239000008101 lactose Substances 0.000 description 4
229910052943 magnesium sulfate Inorganic materials 0.000 description 4
235000019341 magnesium sulphate Nutrition 0.000 description 4
YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 4
239000002808 molecular sieve Substances 0.000 description 4
ZMDILVQIMANXSR-UHFFFAOYSA-N nonan-2-one hydrochloride Chemical compound Cl.CCCCCCCC(C)=O ZMDILVQIMANXSR-UHFFFAOYSA-N 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
KEDNIKLAILXYCS-UHFFFAOYSA-N 3,3-bis(hydroxymethyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C1CNCCC11C(CO)(CO)C(=O)N1C1=CC=CC=C1 KEDNIKLAILXYCS-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102100028646 Nociceptin receptor Human genes 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
230000027455 binding Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008298 dragée Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000001914 filtration Methods 0.000 description 3
150000002466 imines Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000012280 lithium aluminium hydride Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
229910052987 metal hydride Inorganic materials 0.000 description 3
150000004681 metal hydrides Chemical class 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
125000003003 spiro group Chemical group 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
239000001993 wax Substances 0.000 description 3
LPUCHTNHUHOTRY-UHFFFAOYSA-N 1-(3-bicyclo[2.2.1]heptanyl)ethanamine Chemical compound C1CC2C(C(N)C)CC1C2 LPUCHTNHUHOTRY-UHFFFAOYSA-N 0.000 description 2
LMMRZFSAWTYZRD-UHFFFAOYSA-N 1-(9-bicyclo[3.3.1]nonanyl)piperidin-4-one Chemical compound C1CC(=O)CCN1C1C2CCCC1CCC2 LMMRZFSAWTYZRD-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
MTTCPRUJBRANEU-UHFFFAOYSA-N 7-(2,3-dihydro-1h-inden-2-yl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.O=C1CC2(CCN(CC2)C2CC3=CC=CC=C3C2)N1C1=CC=CC=C1 MTTCPRUJBRANEU-UHFFFAOYSA-N 0.000 description 2
CXFCRYUQUQXBSH-UHFFFAOYSA-N 7-(4-methyl-2,3-dihydro-1h-inden-2-yl)-1-phenyl-1,7-diazaspiro[3.5]nonane;hydrochloride Chemical compound Cl.C1C=2C(C)=CC=CC=2CC1N(CC1)CCC21CCN2C1=CC=CC=C1 CXFCRYUQUQXBSH-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000004454 Hyperalgesia Diseases 0.000 description 2
208000035154 Hyperesthesia Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
239000007832 Na2SO4 Substances 0.000 description 2
108090000137 Opioid Receptors Proteins 0.000 description 2
102000003840 Opioid Receptors Human genes 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
230000006399 behavior Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
SXOZDDAFVJANJP-UHFFFAOYSA-N cyclodecanone Chemical compound O=C1CCCCCCCCC1 SXOZDDAFVJANJP-UHFFFAOYSA-N 0.000 description 2
CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 2
JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
BAUZLFKYYIVGPM-UHFFFAOYSA-N cyclononanone Chemical compound O=C1CCCCCCCC1 BAUZLFKYYIVGPM-UHFFFAOYSA-N 0.000 description 2
IIRFCWANHMSDCG-UHFFFAOYSA-N cyclooctanone Chemical compound O=C1CCCCCCC1 IIRFCWANHMSDCG-UHFFFAOYSA-N 0.000 description 2
UPOSSYJVWXLPTA-UHFFFAOYSA-N cycloundecanone Chemical compound O=C1CCCCCCCCCC1 UPOSSYJVWXLPTA-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000003925 fat Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000003446 ligand Substances 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
GXETWWCCWKWBEZ-UHFFFAOYSA-N n-phenyl-1-(4-propan-2-ylcyclohexyl)piperidin-4-imine Chemical compound C1CC(C(C)C)CCC1N(CC1)CCC1=NC1=CC=CC=C1 GXETWWCCWKWBEZ-UHFFFAOYSA-N 0.000 description 2
IATJWQHWZUYXGC-UHFFFAOYSA-N nonane;hydrochloride Chemical compound Cl.CCCCCCCCC IATJWQHWZUYXGC-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
LCVJFHGJMZFJMY-UHFFFAOYSA-N spiro[3.5]nonan-2-one hydrochloride Chemical compound Cl.C1C(CC12CCCCC2)=O LCVJFHGJMZFJMY-UHFFFAOYSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
FFROQSBSJYRALS-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-amine Chemical compound C1CCCC2CC(N)CCC21 FFROQSBSJYRALS-UHFFFAOYSA-N 0.000 description 1
SWZZLAQYTPBAGK-UHFFFAOYSA-N 1-(1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-yl)-4-anilinopiperidine-4-carbonitrile Chemical compound C1CN(C2CC3CCCCC3CC2)CCC1(C#N)NC1=CC=CC=C1 SWZZLAQYTPBAGK-UHFFFAOYSA-N 0.000 description 1
OFNPIQSCTNZDEG-UHFFFAOYSA-N 1-(1,2-dihydroacenaphthylen-1-yl)-4-(3-fluoroanilino)piperidine-4-carbonitrile Chemical compound FC1=CC=CC(NC2(CCN(CC2)C2C=3C=CC=C4C=CC=C(C=34)C2)C#N)=C1 OFNPIQSCTNZDEG-UHFFFAOYSA-N 0.000 description 1
RHRHPGLYUQYUAQ-UHFFFAOYSA-N 1-(1,2-dihydroacenaphthylen-1-yl)-4-(4-fluoroanilino)piperidine-4-carbonitrile Chemical compound C1=CC(F)=CC=C1NC1(C#N)CCN(C2C=3C=CC=C4C=CC=C(C=34)C2)CC1 RHRHPGLYUQYUAQ-UHFFFAOYSA-N 0.000 description 1
FWGQYWSYYASTNY-UHFFFAOYSA-N 1-(1,2-dihydroacenaphthylen-1-yl)-4-(4-methylanilino)piperidine-4-carbonitrile Chemical compound C1=CC(C)=CC=C1NC1(C#N)CCN(C2C=3C=CC=C4C=CC=C(C=34)C2)CC1 FWGQYWSYYASTNY-UHFFFAOYSA-N 0.000 description 1
PWMWNFMRSKOCEY-UHFFFAOYSA-N 1-Phenyl-1,2-ethanediol Chemical compound OCC(O)C1=CC=CC=C1 PWMWNFMRSKOCEY-UHFFFAOYSA-N 0.000 description 1
PIDODLRGSKHQDP-UHFFFAOYSA-M 1-ethyl-1-methylpiperidin-1-ium-4-one;iodide Chemical compound [I-].CC[N+]1(C)CCC(=O)CC1 PIDODLRGSKHQDP-UHFFFAOYSA-M 0.000 description 1
RPCBUMMVFDGODE-UHFFFAOYSA-N 1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1N1C(=O)CC21CCNCC2 RPCBUMMVFDGODE-UHFFFAOYSA-N 0.000 description 1
RHZBRCQIKQUQHQ-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetyl chloride Chemical compound C1=CC=C2C(=O)N(CC(=O)Cl)C(=O)C2=C1 RHZBRCQIKQUQHQ-UHFFFAOYSA-N 0.000 description 1
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
RXDYOLRABMJTEF-UHFFFAOYSA-N 2-chloro-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Cl)C(=O)C1=CC=CC=C1 RXDYOLRABMJTEF-UHFFFAOYSA-N 0.000 description 1
JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
QISAUDWTBBNJIR-UHFFFAOYSA-N 2-phenylmethoxyacetyl chloride Chemical compound ClC(=O)COCC1=CC=CC=C1 QISAUDWTBBNJIR-UHFFFAOYSA-N 0.000 description 1
VFVUGUFTYUATMU-UHFFFAOYSA-N 3,3-bis(hydroxymethyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C1CNCCC11C(CO)(CO)C(=O)N1C1=CC=CC=C1 VFVUGUFTYUATMU-UHFFFAOYSA-N 0.000 description 1
JUCWGQDAFCFNEP-UHFFFAOYSA-N 3,3a,4,5,6,7,8,8a-octahydro-1h-azulen-2-one Chemical compound C1CCCCC2CC(=O)CC21 JUCWGQDAFCFNEP-UHFFFAOYSA-N 0.000 description 1
TZIGOACTZJTCGL-UHFFFAOYSA-N 4-(3-chloroanilino)-1-(1,2-dihydroacenaphthylen-1-yl)piperidine-4-carbonitrile Chemical compound ClC1=CC=CC(NC2(CCN(CC2)C2C=3C=CC=C4C=CC=C(C=34)C2)C#N)=C1 TZIGOACTZJTCGL-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
LAHOQTBRVRATGT-UHFFFAOYSA-N 4-(4-chloroanilino)-1-(1,2-dihydroacenaphthylen-1-yl)piperidine-4-carbonitrile Chemical compound C1=CC(Cl)=CC=C1NC1(C#N)CCN(C2C=3C=CC=C4C=CC=C(C=34)C2)CC1 LAHOQTBRVRATGT-UHFFFAOYSA-N 0.000 description 1
QRGJETBAUPTTQM-UHFFFAOYSA-N 4-anilino-1-(9-bicyclo[3.3.1]nonanyl)piperidine-4-carbonitrile Chemical compound C1CN(C2C3CCCC2CCC3)CCC1(C#N)NC1=CC=CC=C1 QRGJETBAUPTTQM-UHFFFAOYSA-N 0.000 description 1
AYYPQRMTCMCFSL-UHFFFAOYSA-N 4-anilino-1-benzylpiperidine-4-carbonitrile Chemical compound C1CC(C#N)(NC=2C=CC=CC=2)CCN1CC1=CC=CC=C1 AYYPQRMTCMCFSL-UHFFFAOYSA-N 0.000 description 1
LXDIJKGITOQOJV-UHFFFAOYSA-N 7-(1,2,3,3a,4,5,6,7,8,8a-decahydroazulen-2-yl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound O=C1CC2(CCN(CC2)C2CC3CCCCCC3C2)N1C1=CC=CC=C1 LXDIJKGITOQOJV-UHFFFAOYSA-N 0.000 description 1
IBFDYUGFIUXZBF-UHFFFAOYSA-N 7-(1,2,3,3a,4,5,6,7,8,8a-decahydroazulen-2-yl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.O=C1CC2(CCN(CC2)C2CC3CCCCCC3C2)N1C1=CC=CC=C1 IBFDYUGFIUXZBF-UHFFFAOYSA-N 0.000 description 1
ITXIOKGUXQVYIT-UHFFFAOYSA-N 7-(1,2,3,3a,4,5,6,7,8,8a-decahydroazulen-2-yl)-1-phenyl-1,7-diazaspiro[3.5]nonane;hydrochloride Chemical compound Cl.C1CC2(CCN(CC2)C2CC3CCCCCC3C2)N1C1=CC=CC=C1 ITXIOKGUXQVYIT-UHFFFAOYSA-N 0.000 description 1
OUYQUDQSWXVEMV-UHFFFAOYSA-N 7-(1,2-dihydroacenaphthylen-1-yl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound O=C1CC2(CCN(CC2)C2C=3C=CC=C4C=CC=C(C=34)C2)N1C1=CC=CC=C1 OUYQUDQSWXVEMV-UHFFFAOYSA-N 0.000 description 1
WICXQDXKCXTXPF-UHFFFAOYSA-N 7-(2,3,3a,4,5,6-hexahydro-1h-phenalen-1-yl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound O=C1CC2(CCN(CC2)C2C=3C=CC=C4CCCC(C=34)CC2)N1C1=CC=CC=C1 WICXQDXKCXTXPF-UHFFFAOYSA-N 0.000 description 1
NBQABLRWCNTRRC-WLHGVMLRSA-N 7-(2,3,3a,4,5,6-hexahydro-1h-phenalen-1-yl)-1-phenyl-1,7-diazaspiro[3.5]nonane;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CC2(CCN(CC2)C2C=3C=CC=C4CCCC(C=34)CC2)N1C1=CC=CC=C1 NBQABLRWCNTRRC-WLHGVMLRSA-N 0.000 description 1
WLWXTCVYSRVLTB-UHFFFAOYSA-N 7-(2,3-dihydro-1h-inden-2-yl)-3,3-bis(hydroxymethyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C1CN(C2CC3=CC=CC=C3C2)CCC11C(CO)(CO)C(=O)N1C1=CC=CC=C1 WLWXTCVYSRVLTB-UHFFFAOYSA-N 0.000 description 1
KAJGMCRQGLSCPZ-UHFFFAOYSA-N 7-(2,3-dihydro-1h-inden-2-yl)-3,3-bis(hydroxymethyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C1CN(C2CC3=CC=CC=C3C2)CCC11C(CO)(CO)C(=O)N1C1=CC=CC=C1 KAJGMCRQGLSCPZ-UHFFFAOYSA-N 0.000 description 1
JKWAOYGMIVPHJA-UHFFFAOYSA-N 7-(2,3-dihydro-1h-phenalen-1-yl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.O=C1CC2(CCN(CC2)C2C=3C=CC=C4C=CC=C(C=34)CC2)N1C1=CC=CC=C1 JKWAOYGMIVPHJA-UHFFFAOYSA-N 0.000 description 1
DPXIAIRFVNAIGS-UHFFFAOYSA-N 7-(2-oxo-1,2-diphenylethyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C=1C=CC=CC=1C(=O)C(C=1C=CC=CC=1)N(CC1)CCC21CC(=O)N2C1=CC=CC=C1 DPXIAIRFVNAIGS-UHFFFAOYSA-N 0.000 description 1
AIDLEMNQPRFOER-UHFFFAOYSA-N 7-(4-methyl-2,3-dihydro-1h-inden-2-yl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C1C=2C(C)=CC=CC=2CC1N(CC1)CCC21CC(=O)N2C1=CC=CC=C1 AIDLEMNQPRFOER-UHFFFAOYSA-N 0.000 description 1
DNJPBWHCZLXLEI-UHFFFAOYSA-N 7-(4-methyl-2,3-dihydro-1h-inden-2-yl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C1C=2C(C)=CC=CC=2CC1N(CC1)CCC21CC(=O)N2C1=CC=CC=C1 DNJPBWHCZLXLEI-UHFFFAOYSA-N 0.000 description 1
VLUKSUAOAYFSDE-UHFFFAOYSA-N 7-(9-bicyclo[3.3.1]nonanyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound O=C1CC2(CCN(CC2)C2C3CCCC2CCC3)N1C1=CC=CC=C1 VLUKSUAOAYFSDE-UHFFFAOYSA-N 0.000 description 1
CSHDMLCMAJNENF-UHFFFAOYSA-N 7-(9-bicyclo[3.3.1]nonanyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.O=C1CC2(CCN(CC2)C2C3CCCC2CCC3)N1C1=CC=CC=C1 CSHDMLCMAJNENF-UHFFFAOYSA-N 0.000 description 1
MXJNMVMOIRVUPJ-UHFFFAOYSA-N 7-(9-bicyclo[3.3.1]nonanyl)-1-phenyl-1,7-diazaspiro[3.5]nonane;hydrochloride Chemical compound Cl.C1CC2(CCN(CC2)C2C3CCCC2CCC3)N1C1=CC=CC=C1 MXJNMVMOIRVUPJ-UHFFFAOYSA-N 0.000 description 1
VUWSOWDTKGCSHH-UHFFFAOYSA-N 7-(9-bicyclo[6.2.0]decanyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound O=C1CC2(CCN(CC2)C2C3CCCCCCC3C2)N1C1=CC=CC=C1 VUWSOWDTKGCSHH-UHFFFAOYSA-N 0.000 description 1
OYHYLAGIYGVBKY-WLHGVMLRSA-N 7-(9-bicyclo[6.2.0]decanyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.O=C1CC2(CCN(CC2)C2C3CCCCCCC3C2)N1C1=CC=CC=C1 OYHYLAGIYGVBKY-WLHGVMLRSA-N 0.000 description 1
UEXPDKKNCBLYTK-UHFFFAOYSA-N 7-benzyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1CC1=CC=CC=C1 UEXPDKKNCBLYTK-UHFFFAOYSA-N 0.000 description 1
PQXCLWCJYFGDBG-UHFFFAOYSA-N 7-benzyl-3,3-bis(hydroxymethyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C1CN(CC=2C=CC=CC=2)CCC11C(CO)(CO)C(=O)N1C1=CC=CC=C1 PQXCLWCJYFGDBG-UHFFFAOYSA-N 0.000 description 1
KTGRTXQUNBKJEB-UHFFFAOYSA-N 7-benzyl-3-(hydroxymethyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C1CN(CC=2C=CC=CC=2)CCC11C(CO)C(=O)N1C1=CC=CC=C1 KTGRTXQUNBKJEB-UHFFFAOYSA-N 0.000 description 1
ZUKADAPSNLSKSF-UHFFFAOYSA-N 7-benzyl-3-(hydroxymethyl)-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C1CN(CC=2C=CC=CC=2)CCC11C(CO)C(=O)N1C1=CC=CC=C1 ZUKADAPSNLSKSF-UHFFFAOYSA-N 0.000 description 1
GITCALKBAWBJRT-UHFFFAOYSA-N 7-cyclodecyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCCCCC1 GITCALKBAWBJRT-UHFFFAOYSA-N 0.000 description 1
XKWQGORFUSCYNH-UHFFFAOYSA-N 7-cyclododecyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCCCCCCC1 XKWQGORFUSCYNH-UHFFFAOYSA-N 0.000 description 1
GNXFKGACXBHETJ-UHFFFAOYSA-N 7-cyclododecyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCCCCCCC1 GNXFKGACXBHETJ-UHFFFAOYSA-N 0.000 description 1
WUVISZFJGMZJRJ-UHFFFAOYSA-N 7-cycloheptyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCC1 WUVISZFJGMZJRJ-UHFFFAOYSA-N 0.000 description 1
IYZLZMGUXAFUDC-UHFFFAOYSA-N 7-cyclononyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCCCC1 IYZLZMGUXAFUDC-UHFFFAOYSA-N 0.000 description 1
JEAWNSMZVAYLFC-UHFFFAOYSA-N 7-cyclooctyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one;hydrochloride Chemical compound Cl.C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCCC1 JEAWNSMZVAYLFC-UHFFFAOYSA-N 0.000 description 1
FTLPXHANPQQHQU-UHFFFAOYSA-N 7-cyclooctyl-1-phenyl-1,7-diazaspiro[3.5]nonane;hydrochloride Chemical compound Cl.C=1C=CC=CC=1N1CCC1(CC1)CCN1C1CCCCCCC1 FTLPXHANPQQHQU-UHFFFAOYSA-N 0.000 description 1
XGJQIXUHMTVZEC-UHFFFAOYSA-N 7-cycloundecyl-1-phenyl-1,7-diazaspiro[3.5]nonan-2-one Chemical compound C=1C=CC=CC=1N1C(=O)CC1(CC1)CCN1C1CCCCCCCCCC1 XGJQIXUHMTVZEC-UHFFFAOYSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
101150078806 BCAT2 gene Proteins 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
102100026413 Branched-chain-amino-acid aminotransferase, mitochondrial Human genes 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
MLWRTQIQOJRTJJ-YNTFXIJASA-N C(C=CC(=O)O)(=O)O.C(C)(C)[C@H]1CC[C@H](CC1)N1CCC2(C(C(N2C2=CC=CC=C2)=O)OC)CC1 Chemical compound C(C=CC(=O)O)(=O)O.C(C)(C)[C@H]1CC[C@H](CC1)N1CCC2(C(C(N2C2=CC=CC=C2)=O)OC)CC1 MLWRTQIQOJRTJJ-YNTFXIJASA-N 0.000 description 1
VEHLPHAZPSXLLC-KSPSGRDNSA-N C(C=CC(=O)O)(=O)O.C(C1=CC=CC=C1)OC1C(N(C12CCN(CC2)[C@@H]2CC[C@@H](CC2)C(C)C)C2=CC=CC=C2)=O Chemical compound C(C=CC(=O)O)(=O)O.C(C1=CC=CC=C1)OC1C(N(C12CCN(CC2)[C@@H]2CC[C@@H](CC2)C(C)C)C2=CC=CC=C2)=O VEHLPHAZPSXLLC-KSPSGRDNSA-N 0.000 description 1
YOMSZEJVVGTTDO-WGSAOQKQSA-N CC(C)[C@H]1CC[C@@H](CC1)N1CCC2(CC(=O)N2c2ccccc2)CC1 Chemical compound CC(C)[C@H]1CC[C@@H](CC1)N1CCC2(CC(=O)N2c2ccccc2)CC1 YOMSZEJVVGTTDO-WGSAOQKQSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
VLLLHOICJORDSQ-VPLSKCCHSA-N Cl.CC(C)[C@H]1CC[C@@H](CC1)N1CCC2(CC(=O)N2c2ccccc2)CC1 Chemical compound Cl.CC(C)[C@H]1CC[C@@H](CC1)N1CCC2(CC(=O)N2c2ccccc2)CC1 VLLLHOICJORDSQ-VPLSKCCHSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
108010065372 Dynorphins Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
YWKGRWMEVBUKGU-BGYRXZFFSA-N OCC1(C(N(C12CCN(CC2)[C@@H]2CC[C@@H](CC2)C(C)C)C2=CC=CC=C2)=O)CO Chemical compound OCC1(C(N(C12CCN(CC2)[C@@H]2CC[C@@H](CC2)C(C)C)C2=CC=CC=C2)=O)CO YWKGRWMEVBUKGU-BGYRXZFFSA-N 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003574 anti-allodynic effect Effects 0.000 description 1
230000003070 anti-hyperalgesia Effects 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000012024 dehydrating agents‎ Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002081 enamines Chemical class 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000005457 ice water Substances 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
230000007787 long-term memory Effects 0.000 description 1
230000027928 long-term synaptic potentiation Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003399 opiate peptide Substances 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
229910003446 platinum oxide Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002400 pro-nociceptive effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
235000013599 spices Nutrition 0.000 description 1
NRNKZKFTQBNHBT-UHFFFAOYSA-N spiro[3.5]nonan-2-one Chemical compound C1C(=O)CC21CCCCC2 NRNKZKFTQBNHBT-UHFFFAOYSA-N 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Addiction (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)

HR98110804.6A 1998-06-12 1999-06-11 Diaza-spiro /3,5/ nonane derivatives HRP990188A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP98110804		1998-06-12

Publications (1)

Publication Number	Publication Date
HRP990188A2 true HRP990188A2 (en)	2000-02-29

Family

ID=8232114

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR98110804.6A HRP990188A2 (en)	1998-06-12	1999-06-11	Diaza-spiro /3,5/ nonane derivatives

Country Status (28)

Country	Link
US (1)	US6113527A (es)
EP (1)	EP0970957B1 (es)
JP (1)	JP3286268B2 (es)
KR (1)	KR100344732B1 (es)
CN (1)	CN1107066C (es)
AR (1)	AR019859A1 (es)
AT (1)	ATE204279T1 (es)
AU (1)	AU743983B2 (es)
BR (1)	BR9902651A (es)
CA (1)	CA2274202A1 (es)
DE (1)	DE69900220T2 (es)
DK (1)	DK0970957T3 (es)
ES (1)	ES2162503T3 (es)
HR (1)	HRP990188A2 (es)
HU (1)	HU220894B1 (es)
ID (1)	ID23304A (es)
IL (1)	IL130377A0 (es)
MA (1)	MA26644A1 (es)
NO (1)	NO312590B1 (es)
NZ (1)	NZ336189A (es)
PE (1)	PE20000548A1 (es)
PL (1)	PL333695A1 (es)
PT (1)	PT970957E (es)
SG (1)	SG79259A1 (es)
SI (1)	SI0970957T1 (es)
TR (1)	TR199901381A3 (es)
YU (1)	YU26499A (es)
ZA (1)	ZA993852B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030040479A1 (en) *	2001-07-02	2003-02-27	Omeros Corporation	Rotational intrathecal analgesia method and device
WO2003004034A1 (en) *	2001-07-02	2003-01-16	Omeros Corporation	Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US7566728B2 (en) *	2002-03-29	2009-07-28	Mitsubishi Tanabe Pharma Corporation	Remedy for sleep disturbance
JP2005289816A (ja)	2002-05-14	2005-10-20	Banyu Pharmaceut Co Ltd	ベンズイミダゾール誘導体
SI1519939T1 (sl) *	2002-07-05	2010-04-30	Targacept Inc	N-aril diazaspiracikliŽŤne spojine in postopki za njihovo pripravo in njihova uporaba
MXPA05002622A (es) *	2002-09-09	2005-09-08	Johnson & Johnson	Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
GB0323204D0 (en)	2003-10-03	2003-11-05	Novartis Ag	Organic compounds
US20050228023A1 (en) *	2003-12-19	2005-10-13	Sri International	Agonist and antagonist ligands of the nociceptin receptor
US20060178390A1 (en) *	2004-08-02	2006-08-10	Alfonzo Jordan	1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
BRPI0514509A (pt) *	2004-08-20	2008-06-10	Targacept Inc	uso de composto n-aril diazaespiracìclicos no tratamento de dependência
US20080247964A1 (en) *	2006-05-08	2008-10-09	Yuelian Xu	Substituted azaspiro derivatives
MX2009005641A (es) *	2006-11-28	2009-06-05	Janssen Pharmaceutica Nv	Sales de 3-(3-amino-2-(r)-hidroxi-propil)-1-(4-fluoro-fenil)-8-(8- metil-naftalen-1-ilmetil)-1,3,8-triaza-espiro[4,5]deca n-4-ona.
MX2009011006A (es) *	2007-04-09	2009-11-02	Janssen Pharmaceutica Nv	Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion.
KR101704226B1 (ko)	2015-06-30	2017-02-07	현대자동차주식회사	자동차의 쿼터글라스 어셈블리
TW202340202A (zh) *	2021-12-22	2023-10-16	美國加利福尼亞大學董事會	Gtp酶抑制劑及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5756743A (en) *	1996-04-10	1998-05-26	Hoechst Marion Roussel Inc.	Spiro cyclopent b!indole-piperidines!

1999
- 1999-06-07 PT PT99110943T patent/PT970957E/pt unknown
- 1999-06-07 EP EP99110943A patent/EP0970957B1/en not_active Expired - Lifetime
- 1999-06-07 SI SI9930008T patent/SI0970957T1/xx unknown
- 1999-06-07 DE DE69900220T patent/DE69900220T2/de not_active Expired - Lifetime
- 1999-06-07 DK DK99110943T patent/DK0970957T3/da active
- 1999-06-07 ES ES99110943T patent/ES2162503T3/es not_active Expired - Lifetime
- 1999-06-07 AT AT99110943T patent/ATE204279T1/de not_active IP Right Cessation
- 1999-06-08 PE PE1999000487A patent/PE20000548A1/es not_active Application Discontinuation
- 1999-06-08 ID IDP990543D patent/ID23304A/id unknown
- 1999-06-08 ZA ZA9903852A patent/ZA993852B/xx unknown
- 1999-06-09 IL IL13037799A patent/IL130377A0/xx unknown
- 1999-06-09 HU HU9901911A patent/HU220894B1/hu not_active IP Right Cessation
- 1999-06-09 NZ NZ336189A patent/NZ336189A/xx unknown
- 1999-06-09 SG SG9903066A patent/SG79259A1/en unknown
- 1999-06-09 CA CA002274202A patent/CA2274202A1/en not_active Abandoned
- 1999-06-10 YU YU26499A patent/YU26499A/sh unknown
- 1999-06-10 AR ARP990102763A patent/AR019859A1/es active IP Right Grant
- 1999-06-10 KR KR1019990021485A patent/KR100344732B1/ko not_active IP Right Cessation
- 1999-06-10 MA MA25616A patent/MA26644A1/fr unknown
- 1999-06-10 AU AU34987/99A patent/AU743983B2/en not_active Ceased
- 1999-06-10 JP JP16357099A patent/JP3286268B2/ja not_active Expired - Fee Related
- 1999-06-11 CN CN99108373A patent/CN1107066C/zh not_active Expired - Fee Related
- 1999-06-11 PL PL99333695A patent/PL333695A1/xx unknown
- 1999-06-11 HR HR98110804.6A patent/HRP990188A2/hr not_active Application Discontinuation
- 1999-06-11 TR TR1999/01381A patent/TR199901381A3/tr unknown
- 1999-06-11 NO NO19992873A patent/NO312590B1/no unknown
- 1999-06-11 US US09/330,851 patent/US6113527A/en not_active Expired - Fee Related
- 1999-06-11 BR BR9902651-1A patent/BR9902651A/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
ES2162503T3 (es)	2001-12-16
CN1242366A (zh)	2000-01-26
KR100344732B1 (ko)	2002-07-19
DE69900220D1 (de)	2001-09-20
HUP9901911A1 (hu)	2000-05-28
HU9901911D0 (en)	1999-08-30
CN1107066C (zh)	2003-04-30
ATE204279T1 (de)	2001-09-15
YU26499A (sh)	2002-09-19
TR199901381A2 (xx)	2000-01-21
DE69900220T2 (de)	2002-05-08
BR9902651A (pt)	2000-05-16
NO992873L (no)	1999-12-13
SG79259A1 (en)	2001-03-20
KR20000006060A (ko)	2000-01-25
US6113527A (en)	2000-09-05
PT970957E (pt)	2002-02-28
IL130377A0 (en)	2000-06-01
ZA993852B (en)	1999-12-13
EP0970957B1 (en)	2001-08-16
HU220894B1 (en)	2002-06-29
AU743983B2 (en)	2002-02-14
AU3498799A (en)	1999-12-23
ID23304A (id)	2000-04-05
PL333695A1 (en)	1999-12-20
JP2000053679A (ja)	2000-02-22
NO992873D0 (no)	1999-06-11
AR019859A1 (es)	2002-03-20
CA2274202A1 (en)	1999-12-12
TR199901381A3 (tr)	2000-01-21
EP0970957A1 (en)	2000-01-12
PE20000548A1 (es)	2000-07-15
NZ336189A (en)	2000-10-27
JP3286268B2 (ja)	2002-05-27
NO312590B1 (no)	2002-06-03
DK0970957T3 (da)	2001-12-03
SI0970957T1 (es)	2001-12-31
MA26644A1 (fr)	2004-12-20

Legal Events

Date	Code	Title
2000-02-29	A1OB	Publication of a patent application
2000-07-26	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2003-10-21	ODBC	Application rejected

Publication	Publication Date	Title
JP3292457B2 (ja)	2002-06-17	８−置換−１，３，８−トリアザ−スピロ〔４．５〕デカン−４−オン誘導体
EP0921125B1 (en)	2002-01-30	1,3,8-Triazaspiro[4,5]decan-4-on derivatives
HRP990188A2 (en)	2000-02-29	Diaza-spiro /3,5/ nonane derivatives
CA2255171C (en)	2009-09-29	1,3,8-triaza-spiro[4,5]decan-4-on derivatives
AU752835B2 (en)	2002-10-03	Di-or triazaspiro(4.5)decane derivatives
EP0963987B1 (en)	2002-08-28	Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole)
CZ205299A3 (cs)	2000-03-15	Diazospiro[3,5]nonanové deriváty